A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

Inclusion criteria

• Have a body weight of 55 kilogram (kg) or more and body mass index within the range 19.0 to 42.0 kilogram per square meter (kg/m²)
• Additional Inclusion Criteria for Participants Without Hepatic Impairment in Group 1:

• Healthy participants with clinically normal hepatic function
• For Participants with Mild to Severe Hepatic Impairment in Groups 2 through 4:

• Participants with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment). Diagnosis of chronic hepatic impairment of greater than 6 months, per physician diagnosis and standard-of-care practice

Exclusion criteria

• Have significant history of, or current, cardiovascular (CV), respiratory, hepatic (hepatic applies to Group 1 only), renal, gastrointestinal, endocrine, hematological, or neurological disorders
• Have severe atopy or a history of clinically significant multiple or severe drug allergies
• Have known allergies to lepodisiran, related compounds, or any components of the formulation
• Have a history of, or current, psychiatric disorders
• Have had any malignancy within the past 5 years
• Have estimated glomerular filtration rate (eGFR) less than 60 milliliters per minute per 1.73 m² (mL/min/1.73 m²) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
• Have participated, within the last 1 month, in a clinical study involving an investigational product